Definium Therapeutics (DFTX) Total Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has reported Total Liabilities for 7 consecutive years, with $122.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 133.15% year-over-year to $122.4 million; the TTM figure through Mar 2026 stood at $122.4 million (up 133.15% YoY), while the FY2025 annual figure was $107.8 million, up 77.54% from the prior year.
• Total Liabilities grew to $122.4 million in Q1 2026 per DFTX's latest filing, from $107.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $122.4 million in Q1 2026 and bottomed at $9.8 million in Q2 2022.
• Historically, Total Liabilities has averaged $56.1 million across 5 years, with a median of $52.5 million in 2025.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 269.52% — and 2025, when it tumbled 33.92%.
• Definium Therapeutics' Total Liabilities stood at $19.1 million in 2022, then jumped by 143.27% to $46.4 million in 2023, then surged by 30.81% to $60.7 million in 2024, then jumped by 77.54% to $107.8 million in 2025, then gained by 13.61% to $122.4 million in 2026.
• Business Quant data shows DFTX's Total Liabilities at $122.4 million in Q1 2026, $107.8 million in Q4 2025, and $106.3 million in Q3 2025.